These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27293051)

  • 1. Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR).
    Pani L; Montilla S; Németh G; Russo P; Viceconte G; Vogler S
    Pharmacol Res; 2016 Sep; 111():247-250. PubMed ID: 27293051
    [No Abstract]   [Full Text] [Related]  

  • 2. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Japanese drug pricing system: how to balance innovation and the reimbursement system].
    Kurosawa H; Tamura K
    Nihon Yakurigaku Zasshi; 2012 Jun; 139(6):260-3. PubMed ID: 22728989
    [No Abstract]   [Full Text] [Related]  

  • 4. European pharmaceutical pricing and reimbursement conference.
    Ehreth J; Williams D
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):37-9. PubMed ID: 19371177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policies and availability of orphan medicines in outpatient care in 24 European countries.
    Sarnola K; Ahonen R; Martikainen JE; Timonen J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pricing and reimbursement of pharmaceuticals.
    Towse A
    Pharmacoeconomics; 1994; 6 Suppl 1():36-8. PubMed ID: 10155584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inaugural Pharmacogenomics Access and Reimbursement Symposium.
    Rogers SL; Patrinos GP; Mitropoulou C; Formea CM; Jones JS; Brown BG
    Pharmacogenomics; 2021 Jun; 22(9):515-517. PubMed ID: 34032472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third-party payment for nursing services.
    Motta GJ
    Ostomy Wound Manage; 1990; 28():40-3. PubMed ID: 2363800
    [No Abstract]   [Full Text] [Related]  

  • 11. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
    Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
    [No Abstract]   [Full Text] [Related]  

  • 12. Medicaid and indigent care issue brief: Medicaid: provider reimbursement.
    Johnson P
    Issue Brief Health Policy Track Serv; 2000 Jul; ():1-15. PubMed ID: 11073441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in the Access and Cost of Photodynamic Therapy Among Medicare Beneficiaries in the United States, 2012-2017.
    Cheraghlou S; Feng H; Cohen JM
    JAMA Dermatol; 2020 Sep; 156(9):1021-1022. PubMed ID: 32697282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policy interventions related to medicines: Survey of measures taken in European countries during 2010-2015.
    Vogler S; Zimmermann N; de Joncheere K
    Health Policy; 2016 Dec; 120(12):1363-1377. PubMed ID: 27720165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equitable access to polycythemia vera treatments: addressing reimbursement disparities in Europe.
    Breccia M; Barbui T
    Ann Hematol; 2024 Sep; 103(9):3285-3286. PubMed ID: 39046512
    [No Abstract]   [Full Text] [Related]  

  • 16. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis.
    Son KB
    Global Health; 2020 Oct; 16(1):98. PubMed ID: 33054820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategic thinking about health care reform.
    Knapp RM; Fishman LE
    Acad Med; 1992 Jul; 67(7):452-3. PubMed ID: 1616557
    [No Abstract]   [Full Text] [Related]  

  • 18. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices.
    Kolasa K; Kalo Z; Hornby E
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):145-55. PubMed ID: 24964864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Obamacare to markets in artificial organs.
    Malchesky PS
    Artif Organs; 2013 Mar; 37(3):229-32. PubMed ID: 23458329
    [No Abstract]   [Full Text] [Related]  

  • 20. Tackling reimbursement challenges to fair access to medicines - introduction to the topic.
    Tachkov K; Savova A; Manova M; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):597-606. PubMed ID: 37055731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.